In addition to funding continued operations, R and D and manufacturing development, the financing will support further clinical studies, including a multicenter Phase 2b clinical study that will compare ILiAD's lead candidate vaccine, BPZE1, to Boostrix, an FDA-licensed intramuscular acellular pertussis vaccine
. It is anticipated that the Phase 2b study will enroll up to 300 healthy adult volunteers.
The researchers found that median vaccination coverage was 95.1 percent for the state-required number of doses of diphtheria and tetanus toxoids, and acellular pertussis vaccine
; 94.3 percent for two doses of measles, mumps, and rubella vaccine; and 93.8 percent for two doses of varicella vaccine.
Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
(Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012.
He was senior coauthor of a recent study that addresses why acellular pertussis vaccine
immunity wanes so quickly.
A single dose of Quadracel vaccine is approved for use in children four through six years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received four doses of Pentacel and/or DAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine
Adsorbed), stated the company.
Some of our current vaccines don't work as well as we could hope, including the acellular pertussis vaccine
, as Dr.
Pertussis infection is common in SA infants,  and further studies to determine the efficacy or effectiveness of the acellular pertussis vaccine
will almost certainly be needed.
(12,13) Another recent trial investigating the acellular pertussis vaccine
found that immunity decreases dramatically 5 years after the fifth dose.
The acellular pertussis vaccine
is more purified and uses only selected portions of the pertussis bacteria to stimulate an immune response.
"Studies have suggested that protection following the acellular pertussis vaccine
is less enduring than following the whole-cell pertussis vaccine," said lead study author Nicola Klein, MD, PhD, of the Kaiser Permanente Vaccine Study Center.
For example, the older whole cell pertussis vaccine causes the production of about 3000 different antibodies, whereas the newer acellular pertussis vaccine
causes the production of 6 or fewer different antibodies.
Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine
or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997.